<- Go Home
PolyPid Ltd.
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Market Cap
$87.0M
Volume
173.4K
Cash and Equivalents
$8.9M
EBITDA
-$31.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$5.12
52 Week Low
$2.44
Dividend
N/A
Price / Book Value
9.96
Price / Earnings
-2.56
Price / Tangible Book Value
9.96
Enterprise Value
$78.5M
Enterprise Value / EBITDA
-2.47
Operating Income
-$33.1M
Return on Equity
758.61%
Return on Assets
-115.07
Cash and Short Term Investments
$10.9M
Debt
$2.3M
Equity
$8.8M
Revenue
N/A
Unlevered FCF
N/A
Sector
Pharmaceuticals
Category
N/A